Use of Sodium Channel Blockers in the Thr226Met Pathologic Variant of SCN1A: A Case Report

Abstract

The Thr226Met pathologic variant of the SCN1A gene has been associated with the clinical development of an early infantile developmental and epileptic encephalopathy (EIDEE) different from Dravet's syndrome. The electrophysiological mechanisms of the mutated channel lead to a paradoxical gain and loss of function. The use of sodium channel blockers (SCB) that counteract this gain of function has been described in previous studies and they can be safely administered to patients carrying mutations in other sodium channel subtypes without causing a worsening of seizures. We report the use of SCB in a child harboring the Thr226Met pathologic variant of SCN1A with early-onset pharmaco-resistant migrating seizures, as well as developmental delay. Lacosamide led to a dramatic reduction in seizure frequency; however, only a mild improvement in the epileptic activity depicted by electroencephalography (EEG) was achieved. The introduction of carbamazepine as an add-on therapy led to a notable reduction in epileptic activity via EEG and to an improvement in sensorimotor development. Despite the overall clinical improvement, the patient developed febrile seizures and a nonepileptic jerking of the right hand. In this case of EIDEE with the Thr226Met variant, we demonstrate a beneficial pharmacological intervention of SCB in contrast to findings described in current literature. Our report encourages the cautious use of SCB at early stages of the disease in patients carrying this pathologic variant.

Keywords

SCN1A - Thr226Met - early infantile developmental and epileptic encephalopathy - sodium channel blocker - gain and loss of function - voltage gated sodium channel

Publikationsverlauf

Eingereicht: 04. Dezember 2022

Angenommen: 09. März 2023

Accepted Manuscript online:
19. Juli 2023

Artikel online veröffentlicht:
18. September 2023

• References

• 1 Brunklaus A, Brünger T, Feng T. et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain 2022; 145 (11) 3816-3831
• 2 Meng H, Xu HQ, Yu L. et al. The SCN1A mutation database: updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Hum Mutat 2015; 36 (06) 573-580
• 3 Zuberi SM, Brunklaus A, Birch R, Reavey E, Duncan J, Forbes GH. Genotype-phenotype associations in SCN1A-related epilepsies. Neurology 2011; 76 (07) 594-600
• 4 Ogiwara I, Miyamoto H, Morita N. et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 2007; 27 (22) 5903-5914
• 5 Berecki G, Bryson A, Terhag J. et al. SCN1A gain of function in early infantile encephalopathy. Ann Neurol 2019; 85 (04) 514-525
• 6 Sadleir LG, Mountier EI, Gill D. et al; DDD Study. Not all SCN1A epileptic encephalopathies are Dravet syndrome: early profound Thr226Met phenotype. Neurology 2017; 89 (10) 1035-1042
• 7 Bikson M, Hahn PJ, Fox JE, Jefferys JGR. Depolarization block of neurons during maintenance of electrographic seizures. J Neurophysiol 2003; 90 (04) 2402-2408
• 8 Liao WP, Shi YW, Long YS. et al. Partial epilepsy with antecedent febrile seizures and seizure aggravation by antiepileptic drugs: Associated with loss of function of Nav1.1: PEFS+ and Loss of Function of Nav1.1. Epilepsia 2010; 51 (09) 1669-1678
• 9 Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000; 26 (01) 13-25
• 10 Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009; 5: 757-766
• 11 Wang W, Takashima S, Segawa Y. et al. The developmental changes of Na(v)1.1 and Na(v)1.2 expression in the human hippocampus and temporal lobe. Brain Res 2011; 1389: 61-70
• 12 Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res 2015; 110: 189-205
• 13 Peters C, Rosch RE, Hughes E, Ruben PC. Temperature-dependent changes in neuronal dynamics in a patient with an SCN1A mutation and hyperthermia induced seizures. Sci Rep 2016; 6 (01) 31879
• 14 Volkers L, Kahlig KM, Das JHG. et al. Febrile temperatures unmask biophysical defects in Nav1.1 epilepsy mutations supportive of seizure initiation. J Gen Physiol 2013; 142 (06) 641-653